Table 3 Results of analysis of risk factors for PFS and OS
Factors | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
univariate | multivariate | Univariate | multivariate | |||||
HR(95%CI) | P value | HR(95%CI) | P value | HR(95%CI) | P value | HR(95%CI) | P value | |
Age (As a numerical variate) | 1.013 (0.991–1.036) | 0.247 | 1.008 (0.982–1.034) | 0.559 | 1.011 (0.984–1.038) | 0.429 | 0.998 (0.969–1.027) | 0.871 |
Sex | ||||||||
Male | 1.280 (0.630–2.598) | 0.495 | 1.207 (0.560–2.599) | 0.631 | 1.625 (0.678–3.897) | 0.277 | 1.545 (0.594–4.016) | 0.372 |
Female | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | – |
Cytogenetics and Molecular Risk | ||||||||
Favorable | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | – |
Intermediate | 1.459 (0.501–4.252) | 0.489 | 1.573 (0.469–5.280) | 0.463 | 4.190 (0.555–31.654) | 0.165 | 2.743 (0.294–25.590) | 0.376 |
Adverse | 1.538 (0.433–5.462) | 0.506 | 1.809 (0.484–6.768) | 0.379 | 4.011 (0.446–36.050) | 0.215 | 6.744 (0.676–67.256) | 0.104 |
Number of Induction Therapy Courses to achieve MRD-negative CR | ||||||||
1 | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | – |
More than 1 | 0.743 (0.359–1.539) | 0.424 | 0.655 (0.286–1.498) | 0.316 | 0.686 (0.284–1.660) | 0.404 | 0.494 (0.188–1.295) | 0.151 |
Consolidation Regimen | ||||||||
AML-87 | 0.798 (0.320–1.987) | 0.627 | 1.019 (0.318–3.266) | 0.975 | 1.274 (0.414–3.921) | 0.673 | 1.858 (0.441–7.820) | 0.398 |
AML-201 | 0.652 (0.252–1.687) | 0.377 | 0.892 (0.320–2.488) | 0.827 | 0.372 (0.093–1.493) | 0.163 | 0.374 (0.088–1.592) | 0.183 |
HDAra-C | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | – |
DPLT | ||||||||
Hlgh | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | – |
Low | 3.106 (1.509–6.394) | 0.002 | 2.894 (1.320–6.345) | 0.008 | 2.525 (1.056–6.035) | 0.037 | 3.077 (1.130–8.376) | .0.028 |